LivaNova’s (LIVN) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $62.00 price target on the stock.

A number of other analysts have also recently weighed in on LIVN. Mizuho increased their price target on shares of LivaNova from $53.00 to $60.00 in a research note on Thursday, July 27th. Barclays raised their target price on shares of LivaNova from $51.00 to $57.00 and gave the stock an equal weight rating in a research note on Thursday, July 27th. StockNews.com began coverage on shares of LivaNova in a research note on Thursday, October 5th. They issued a buy rating for the company. Robert W. Baird raised their target price on shares of LivaNova from $56.00 to $62.00 in a research note on Thursday, July 27th. Finally, HSBC began coverage on shares of LivaNova in a research note on Wednesday, September 6th. They issued a hold rating and a $52.00 target price for the company. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and a consensus target price of $59.33.

LivaNova Trading Up 0.2 %

NASDAQ LIVN opened at $46.86 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.23 and a quick ratio of 2.68. The firm’s fifty day moving average price is $50.71 and its 200 day moving average price is $51.15. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 937.20 and a beta of 0.89. LivaNova has a 12 month low of $40.26 and a 12 month high of $59.86.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.09. The firm had revenue of $286.10 million during the quarter, compared to analysts’ expectations of $271.97 million. LivaNova had a net margin of 0.27% and a return on equity of 12.10%. LivaNova’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.58 EPS. On average, sell-side analysts expect that LivaNova will post 2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE boosted its position in LivaNova by 14.0% in the first quarter. US Bancorp DE now owns 1,840 shares of the company’s stock valued at $80,000 after buying an additional 226 shares in the last quarter. Barclays PLC lifted its position in shares of LivaNova by 10.2% during the second quarter. Barclays PLC now owns 735,028 shares of the company’s stock worth $37,803,000 after purchasing an additional 68,100 shares in the last quarter. Guggenheim Capital LLC lifted its position in shares of LivaNova by 1,016.5% during the first quarter. Guggenheim Capital LLC now owns 122,766 shares of the company’s stock worth $5,350,000 after purchasing an additional 111,770 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of LivaNova during the first quarter worth approximately $529,000. Finally, Greenlight Capital Inc. lifted its position in shares of LivaNova by 23.4% during the first quarter. Greenlight Capital Inc. now owns 1,034,896 shares of the company’s stock worth $45,101,000 after purchasing an additional 196,496 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.